Eisai has put direct-to-consumer (DTC) advertising at the heart of its ongoing efforts to expand demand for Leqembi. | Eisai ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

EMA’s reluctance in approving drugs for the condition underscores Europe’s prioritisation of long-term safety over rapid ...

Leqembi market analysis highlights key dynamics, including growth potential driven by increased Alzheimer's prevalence, advancements in treatments, and innovations in IV dosing. Key player Eisai Co.

The Food and Drug Administration (FDA) has cleared Lumipulse G for U.S. commercialization as the first blood-based test that ...

Hi, it’s Amber in Hong Kong. Across the strait in Taiwan, breakthrough Alzheimer’s drugs are finally becoming available but ...

U.S. health officials on Friday endorsed the first blood test that can help diagnose Alzheimer’s and identify patients who ...

Leqembi (lecanemab-irmb) is a prescription drug that’s used to treat Alzheimer’s disease. The drug comes as a liquid that’s given as an infusion into a vein. It’s usually given once every ...

U.S. regulators have approved the first blood test to help diagnose Alzheimer’s disease, potentially making it easier to find ...

The Food and Drug Administration has cleared Fujirebio Diagnostics’ blood test to diagnose Alzheimer’s disease, the regulator ...

The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's disease, the ...